The aim of this study is to identify the factors independently associated with mortality in ICU patients A total of 108 patients were finally included in the study. The most frequent source of infection was unknown focus bacteremia in 52 (48.1%) patients. The rate of resistance to colistin was 50%; 30-day mortality was estimated as 26.1%. Surviving patients were more frequently treated with an initial therapy (within 24 hours) including ≥2 antibiotics displaying in vitro activity against the isolated KPCKp strain (41.8% Vs 19.5%, p<0.001), and were also more likely to receive a definitive therapy including ≥2 in vitro active antibiotics (85.1% Vs 17%, p<0.001). Cox regression analysis revealed that a colistin-containing antibiotic regimen (Hazard ratio [HR] 0.31, CI 95% 0.09-0.52, p<0.001), the use of ≥2 in vitro active antibiotics as definite therapy (HR 0.09, CI 95% 0.04-0.15, p<0.001), and control of removable source of infection (HR 0.12, CI 95% 0.08-0.19, p<0.001) were associated with favorable outcome; colistin-resistance (HR 6.12, CI 95% 2.14-9.33, p=0.01), KPC rectal colonization at time of ICU admission (HR 2.87, CI 95% 1.23-3.12, p<0.001), and intra-abdominal source of infection (HR 3.12, CI 95% 2.09-4.24, p=0.002) were associated with death.
INTRODUCTION
The emergence of Klebsiella pneumoniae (Kp) strains that produce Klebsiella pneumoniae outcome. KPC-producing isolates of Kp (KPC-Kp) are not only able to hydrolyze carbapenems, but are often resistant to a variety of other antibiotics, including colistin and aminoglycosides. These organisms caused numerous infection outbreaks in the United States, Israel, and South Europe where they are now considered endemic [1] . Most reports have analyzed the molecular epidemiological aspects or the antimicrobial susceptibility profiles, but less attention has been deserved to the antimicrobials used and to the related patient outcomes [2-3-4-5-6-7] .
Effective treatment of infections caused by these pathogens is thus a considerable challenge for clinicians [8] [9] . Treatment options are usually limited to colistin, gentamicin, and/or tigecycline in association with a carbapenem [10] , but the optimal regimen for infections caused by KPC-Kp has yet to be defined. Moreover, studies of infections caused by these organisms indicate that combination therapies are often more effective than monotherapies [11-12-13] , but the identification of the best treatment regimen will require larger studies with more in-depth analysis of clinical characteristics and outcomes.
Very few data exist about the mortality predictors in Intensive Care Unit (ICU) patients with KPC-Kp infection and septic shock. This study is aimed to analyze the risk factors for mortality and to identify the procedures and antimicrobial regimens associated with improved outcome in such life-threatening clinical situation. The study was conducted at the University-Hospital Policlinico Umberto I, Rome, Italy. All patients hospitalized in the ICU who developed a septic shock due to KPC-Kp, from November 2010 to December 2014, were retrospectively analyzed. Patients who fulfilled the following criteria were enrolled in the study: 1) age 18 years or over; 2) severe sepsis or septic shock due to KPC-Kp infection; 3) treatment of infection for at least 24 hours.
PATIENTS AND METHODS

Study Design and Patient Selection
The present study was conducted according to the principles stated in the Declaration of Helsinki. The local Ethical Committee approved the study.
Baseline Assessment, Definitions and Endpoints
Data were extracted from the medical records of patients and from hospital computerized databases or clinical charts according to a prepared questionnaire. The following data were reviewed:
demographics, clinical and laboratory findings, comorbid conditions (like diabetes mellitus, cardiovascular disease, pulmonary disease, renal disease, hepatic disease, central nervous system disease, malignancy, and the overall number of comorbid conditions), microbiological data, duration of ICU and hospital stay, incidence of infections during hospitalization, treatments and procedures during hospitalization and/or in the previous 90 days prior to infection (immunosuppressive therapy, placement of a central venous catheter [CVC] or a urinary catheter, dialysis, endoscopic procedures, tracheostomy, surgery, and mechanical ventilation), admission from a long-term care facility or a nursing home, classes of antibiotics received on admission and/or after admission before a positive culture was obtained, the simplified acute physiology score (SAPS II) score at time of infection, source of infection, antibiotic regimens against KPC-Kp infections, and mortality.
Infections were defined according to the standard definitions of the European Centers for Disease Control and Prevention (eCDC) [14] .
The following terms were defined prior to data analysis. A KPC-Kp infection was defined as an infection documented by culture positivity for a KPC-Kp strain by site of infection (blood, lung, skin and soft-tissue, CVC, urinary tract, abdomen) and clinical signs of the systemic inflammatory response syndrome [15] . Infection onset was defined as the date of collection of the index culture (i.e., the first blood culture that yielded the study isolate). Infections were defined as hospital-acquired if the index culture had been collected >48 hours after hospital admission and no signs or symptoms of infection The CVC was considered like source of infection if blood culture obtained from the lumen of the catheter was positive in a time <2 hours compared to peripheral veins, and/or culture of catheter was positive [16] .
Severe sepsis was defined as sepsis with sepsis-induced organ dysfunction or tissue hypoperfusion (manifesting as hypotension, elevated lactate, or decreased urine output); septic shock as severe sepsis plus persistently low blood pressure following the administration of intravenous fluids [17] . The severity of clinical conditions was also determined by use of SAPS II score calculated at the time of septic shock syndrome onset [18] .
Length of hospital and ICU stay were calculated as the number of days from the date of admission to the date of discharge or death. Length of hospital stay prior to KPC-Kp infection was calculated as the number of days from the date of admission in hospital to the date of KPC-Kp isolation.
Early acquisition of infection was defined as acquisition of KPC-Kp infection at admission in ICU and in the first 7 days of ICU stay; late acquisition of infection was defined as acquisition of KPC-Kp infection after 7 days of ICU stay.
Evaluation of factors associated with mortality after development of septic shock due to KPC-Kp was the primary end-point of the study. 
Antimicrobial Treatment Evaluation and Control of Source of Infection
Microbiology, KPC Identification, and Antimicrobial Susceptibilities
The Vitek 2 automated system (bioMérieux, Marcy l'Etoile, France) was used for isolate identification and antimicrobial susceptibility testing. Minimum inhibitory concentrations (MICs) were classified according to breakpoints established by the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) [19] . Susceptibility to tigecycline was evaluated by Etest technique, to avoid MIC overestimation for this drug by use of Vitek2 system, and US Food and Drug Administration (FDA) recommendation was used for definitions (susceptible, MIC ≤ 2 mg/L; resistant, MIC ≥ 8 mg/L) [20-21-22-23] . The presence of a blaKPC gene was determined by polymerase chain reaction and sequencing [24] .
Statistical Analysis
The results obtained were analyzed using a commercially available statistical software packages (SPSS, version 20.0; SPSS Inc, Chicago, Illinois).
To detect significant differences between groups, we used the chi- The 30-day mortality rate was 26.1%. As described in Table 1 at univariate analysis, among surviving patients the most common causes of ICU admission were trauma (23.9% of cases), while was surgery among non-surviving patients (24.4% of cases). The median length of ICU stay prior to KPC-Kp infection was 4 ± 4 among survivors, and 23 ± 5 among non-survivors (p<0.001), while no statistically significant differences were reported about the time spent in ICU during hospitalization among surviving and non-surviving patients. As regards to the source of infection, an intra-abdominal focus was more frequently recognized in non-surviving patients (24.4%), while control of removable source of infection was obtained in the 41.8% of surviving compared to 12.2% of non-surviving patients (p=0.001). The isolation of colistin-resistant KPC-Kp was significantly more frequent in non-surviving patients compared to surviving patients (80.5% vs 31.3%, respectively; p<0.001), and the median of SAPS II score was also higher among non-surviving patients (p =0.012). Cox regression analysis, presented in Table 3 , demonstrates that a colistin-containing regimen, the use of ≥2 in vitro active antibiotics as definite therapy, and control of removable source of infection are independently associated with favorable outcome; on the contrary, infection due to a colistin-resistant strain, KPC colonization at time of admission in ICU, and intra-abdominal source of infection are independently associated with death. Previous studies have showed that the use of multiple antibiotics therapies improves outcomes in patients with KPC-Kp infection and the combination of colistin, meropenem and tigecycline has been found to be associated with better survival rates [12, 25] . However, when we analyzed the impact of different antibiotic strategies in determining outcome of patients with septic shock due to KPC-Kp we noted that a factor independently associated with improved survival was the administration of at least two in vitro active antibiotics. Thus our study seems to suggest that is not so important the number of drugs used or a specific antibiotic combination, but the delivery drugs having in vitro activity against the isolated strain. Since all KPC-Kp strains isolated in our population were susceptible to tigecycline, another key message of this study is that susceptibility to colistin appears as the most important determinant of outcome, since resistance to this agent was associated with death. This finding seems to confirm a previous observation in patients hospitalised in our geographic area [26] .
Pharmacokinetic/pharmacodynamics data show that colistin, when used at very high dose, may reach adequate serum concentrations in critically ill patients with septic shock [13, 27] . Under these circumstances its clinical efficacy against KPC-Kp might be further improved by synergistic combination with other agents. Of interest, we also noted at univariate analysis a trend of improved survival when a gentamicin-based regimen was used (p=0.03); this last finding confirms some recent in vitro and clinical data highlighting a role of gentamicin in this setting [28] [29] .
The basic management principles of septic shock focus on 3 key elements: early appropriate antimicrobial therapy [30] [31] , hemodynamic resuscitation, and adequate source control [17, 32] . In our population fluid administration and the use of vasopressors were similar between survivors and nonsurvivors patients and were based on goal-directed endpoints at our institution during the study period [33] . As expected, we found that an early source control is crucial even in the case of septic shock due Another factor independently associated with death is KPC colonization at time of ICU admission. The evidence of KPC-Kp colonization at the time of ICU admission is very uncommon in patients without any previous healthcare contract and accessing to ICU from the community (e.g. after trauma), while may be more common in elderly patients with history of recent hospitalization and/or receiving antibiotic therapies or following transfer from medical or surgical wards [34] . It can be assumed that the initial KPC-Kp colonization probably represents a marker of severity of clinical conditions and is more frequent in patients with a history of prolonged hospitalization prior the admission to ICU [35] .
Thus, it is not surprising that the patients already colonized at the time of ICU admission had a high likelihood to die. However, this finding suggests a careful monitoring of patients already colonized by KPC-Kp at the time of ICU admission since development of septic shock in these cases may be fatal [36] .
There are some important limitations of our study that should be acknowledged. First, the study was performed at a single-center and the results may not be generalizable to other institutions. Second, the retrospective nature of the study is an intrinsic limitation of this analysis. Third, the number of patients is relatively low and further multicentric, prospective studies are needed to confirm our findings.
However this is a real-life clinical experience providing useful suggestions to clinicians about the management of a difficult-to-treat and poorly studied infection like septic shock caused by KPC-Kp.
In conclusion, we identified that a colistin-based therapy, the use of a definitive antibiotic therapy including two or more antibiotics displaying in vitro activity against the KPC-Kp isolates, and control *During the study period the usual antimicrobial dosages, adopted for the most used antibiotics, were the following:
for colistin a loading dose of 6-9 milions IU followed by 3 milions IU every 8 hours (in the period 2010-2011) or a loading dose of 9 milions IU followed by 4.5 milions IU every 12 hours; for tigecycline a loading dose of 150-200 mg followed by 100 mg every 12 hours; for gentamicin a dosage of 5 mg/kg every 24 hours; for meropenem a dosage of 2 g every 8 hours or 1.5 g every 6 hours. 
